ALTER-DOMUS
17.11.2021 14:02:13 CET | Business Wire | Press release
Alter Domus (“Alter Domus” or the “Company”), a leading provider of integrated solutions for the alternative investment industry, announced it has signed a strategic partnership agreement with NTT Ltd ., a world-leading global technology services provider, to accelerate the company’s innovation journey and enhance the company’s digital workplace for all employees.
The partnership will introduce a 24/7/365 global online service desk supplemented by scheduled local visits to deliver responsive and high touch support to all Alter Domus staff.
ServiceNow, a leading cloud-based platform, is the foundation of the new service desk capability and will be accessible to Alter Domus employees in Europe and Asia Pacific, providing them with access to a full IT support portfolio. This new generation smart ticketing system will be characterised by fast, premium support service in just a few clicks.
In addition to upgrading IT service capabilities, the scope of the Alter Domus-NTT partnership will involve the transition to a new data centre. Several other transformation projects will progress over the coming months, including supporting the company with its cloud adoption journey and bolstering its IT security systems using NTT’s extensive expertise and broad technology offering.
Darren O’Banion, Chief Technology Officer at Alter Domus, said : “We aim to elevate our IT infrastructure to support our global growth and ensure Alter Domus’ clients and employees can rely on our scalable, high performing and secure platform. We are pleased to have signed this strategic partnership with NTT and look forward to a smooth transition in this next phase of our innovation journey.”
Abhijit Dubey, Global CEO at NTT Ltd., said: “We’re thrilled that Alter Domus chose NTT to support them to modernize their IT infrastructure as well as to transform and improve their employee experience. NTT’s proven intelligent infrastructure services and continuous innovation in digital workspace will enable Alter Domus to accelerate their global expansion.”
Olivier Posty, Managing Director for NTT Ltd. in Luxembourg added: “We’re very excited about the start of our collaboration with Alter Domus, a success story made in Luxembourg, and we’re looking forward to help them achieve their digital transformation goals globally by leveraging our team in Luxembourg and our experts from around the globe.”
# # #
About Alter Domus
Alter Domus is a leading provider of integrated solutions for the alternative investment industry. Vertical integration allows us to build dedicated teams to provide support and bespoke solutions across entire value chains. By tapping into a talent pool of some 3,300 employees across more than 35 offices in 21 countries, our expertise and cutting-edge technology combine to put clients ahead of the game.
With an established professional focus on private equity, infrastructure, real estate, and debt capital markets sectors, we offer fund administration, corporate services, depositary services, transfer pricing, capital administration, domiciliation and management company services. Our specific experience in the debt capital markets sector allows us to provide specialist solutions such as agency services, loan administration, trade settlement and CLO manager services.
For more information, please visit: www.alterDomus.com .
About NTT Ltd.
NTT Ltd. is a leading, global technology services company. To help our clients achieve their digital transformation goals, we use our global capabilities, expertise, and full-stack technology services delivered through our integrated services platform. As their long-term strategic partner, we help them enhance customer and employee experience, transform their cloud strategy, modernize their networks and strengthen their cybersecurity. And across their transformation priorities, we automate their business processes and IT, drawing insights and analytics from their core business data. As a global ICT provider, we employ more than 50,000 people across 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005827/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom